Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7128583 | 0.90 | DPP4 (0.49) | SMN1; SMN2RECQLDPP4ALDH1A1KDM4E | |
| SCHEMBL8186246 | 0.86 | ALDH1A1 (0.61) | SMN1; SMN2HRH3ALDH1A1KDM4ELMNA | |
| SCHEMBL6973800 | 0.83 | JAK2 (0.53) | SMN1; SMN2RECQLALDH1A1KDM4EACHE | |
| SCHEMBL6974039 | 0.82 | MC4R (0.58) | SMN1; SMN2RECQLKDM4EACHELMNA | |
| SCHEMBL3959065 | 0.80 | ACHE (0.66) | CYP2D6SMN1; SMN2RECQLHRH3ALDH1A1 | |
| SCHEMBL1943497 | 0.79 | HRH3 (0.75) | CYP2D6SMN1; SMN2HRH3ALDH1A1KDM4E | |
| SCHEMBL642022 | 0.78 | SIGMAR1 (0.55) | SMN1; SMN2RECQLDPP4ALDH1A1KDM4E | |
| SCHEMBL13812393 | 0.78 | ACHE (0.57) | CYP2D6SMN1; SMN2RECQLHRH3ALDH1A1 | |
| SCHEMBL1895069 | 0.75 | CYP2D6 (0.54) | CYP2D6SMN1; SMN2HRH3ALDH1A1HSD11B1 | |
| SCHEMBL8193615 | 0.75 | SIGMAR1 (0.55) | SMN1; SMN2RECQLACHELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176445-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. | 2003-09-18 | — | — | US | disclosed |
| EP-1106615-B1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020042421-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | OKUMURA YOSHIYUKI (JP) | 2002-04-11 | — | — | US | disclosed |
| EP-1106615-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176445-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | CYP2D6 786/4885SMN1; SMN2 4652/4885RECQL 3084/4885 |
| US-20020042421-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | CYP2D6 818/4885SMN1; SMN2 4681/4885RECQL 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.